Topic Highlight
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 7, 2013; 19(45): 8181-8187
Published online Dec 7, 2013. doi: 10.3748/wjg.v19.i45.8181
Helicobacter pylori and gastric mucosa-associated lymphoid tissue lymphoma: Recent progress in pathogenesis and management
Shotaro Nakamura, Takayuki Matsumoto
Shotaro Nakamura, Department of R/D for Surgical Support System, Center for Advanced Medical Innovation, Kyushu University, Fukuoka 812-8582, Japan
Shotaro Nakamura, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
Takayuki Matsumoto, Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University, Morioka 020-8505, Japan
Author contributions: Nakamura S and Matsumoto T contributed equally to this manuscript.
Correspondence to: Shotaro Nakamura, MD, PhD, Department of R/D for Surgical Support System, Center for Advanced Medical Innovation, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. shonaka@intmed2.med.kyushu-u.ac.jp
Telephone: +81-92-6424733 Fax: +81-92-6424741
Received: September 25, 2013
Revised: October 22, 2013
Accepted: November 3, 2013
Published online: December 7, 2013
Processing time: 83 Days and 12.4 Hours
Abstract

Recent progress in the research regarding the molecular pathogenesis and management of gastric mucosa-associated lymphoid tissue (MALT) lymphoma is reviewed. In approximately 90% of cases, Helicobacter pylori (H. pylori) infection plays the causative role in the pathogenesis, and H. pylori eradication is nowadays the first-line treatment for this disease, which leads to complete disease remission in 50%-90% of cases. In H. pylori-dependent cases, microbe-generated immune responses, including interaction between B and T cells involving CD40 and CD40L co-stimulatory molecules, are considered to induce the development of MALT lymphoma. In H. pylori-independent cases, activation of the nuclear factor-κB pathway by oncogenic products of specific chromosomal translocations such as t(11;18)/API2-MALT1, or inactivation of tumor necrosis factor alpha-induced protein 3 (A20) are considered to contribute to the lymphomagenesis. Recently, a large-scale Japanese multicenter study confirmed that the long-term clinical outcome of gastric MALT lymphoma after H. pylori eradication is excellent. Treatment modalities for patients not responding to H. pylori eradication include a “watch and wait” strategy, radiotherapy, chemotherapy, rituximab immunotherapy, and a combination of these. Because of the indolent behavior of MALT lymphoma, second-line treatment should be tailored in consideration of the clinical stage and extent of the disease in each patient.

Keywords: Gastric lymphoma; Mucosa-associated lymphoid tissue lymphoma; Helicobacter pylori; Nuclear factor κB

Core tip: Recent progress in the research regarding the molecular pathogenesis and management of gastric mucosa-associated lymphoid tissue (MALT) lymphoma is reviewed. Helicobacter pylori (H. pylori) eradication leads to complete disease remission in 50%-90% of cases. In H. pylori-independent cases, activation of nuclear factor κB pathway by chromosomal translocations such as t(11;18)/API2-MALT1, or inactivation of A20 are considered to contribute to the lymphomagenesis. A recent Japanese multicenter study confirmed the excellent long-term outcome of gastric MALT lymphoma after H. pylori eradication. Strategies for patients not responding to H. pylori eradication should be tailored in consideration of clinical stage and the disease extent in each patient.